The role of axonopathy in Parkinson's disease.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3214783)

Published in Exp Neurobiol on December 31, 2010

Authors

Karen L O'Malley1

Author Affiliations

1: Department of Anatomy and Neurobiology, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, Missouri, 63110, USA.

Articles cited by this

Parkinson's disease: mechanisms and models. Neuron (2003) 14.84

PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol (2010) 11.85

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85

Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06

The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51

Axonal self-destruction and neurodegeneration. Science (2002) 4.30

Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci (2001) 4.10

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24

Axonal mitochondrial transport and potential are correlated. J Cell Sci (2004) 3.15

Parkinson's disease. Lancet (2004) 3.08

Axonal transport defects in neurodegenerative diseases. J Neurosci (2009) 2.74

Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38

Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci (2009) 2.15

Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain (2007) 2.10

Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci (2009) 1.78

Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci (2008) 1.54

Mitochondrial transport and docking in axons. Exp Neurol (2009) 1.41

Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem (2005) 1.38

Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci (2004) 1.36

Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience (2003) 1.34

The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor. FEBS Lett (2005) 1.16

Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp Neurol (2006) 1.13

Axonal degeneration and regeneration: a mechanistic tug-of-war. J Neurochem (2008) 1.10

Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis (2010) 1.10

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol (2006) 1.09

Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol (2009) 0.95

Parkinson's disease: Exit toxins, enter genetics. Prog Neurobiol (2009) 0.95

Mitochondrial dynamics and neurodegeneration. Curr Neurol Neurosci Rep (2009) 0.93

Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. Mol Neurodegener (2010) 0.89